Bullish & Foolish
Full INO fundamentals All 466 on the Survival Watch

INOINOVIO PHARMACEUTICALS, INC.

Is Inovio Pharmaceuticals struggling financially?

Yes, by its own account. Inovio Pharmaceuticals told the SEC on 12 Aug 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Aug 2026

15/100

Critical

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Trial result

    However, in May 2026, our collaborator ApolloBio Corporation announced positive topline results from their ongoing Phase 3 clinical trial of this candidate in China.

    Form 10-Q, filed 12 Aug 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$122.0M
Source filing
10-Q 12 Aug 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$36.7M

÷

Cash burned over the last 12 months

$88.9M

What Inovio Pharmaceuticals told the SEC

…that rely on delivery by such devices. We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern. We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain. We have incurred…

INOVIO PHARMACEUTICALS, INC., Form 10-Q, filed 12 Aug 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 94.7% share-count increase The company issued stock. Each share now owns 48.6% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 50% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt